Abstract
Background:Advanced breast cancer is difficult to treat due tothe primary and acquired resistance, which is the main cause of rescue treatment failure. Therefore, developing a new rescue treatment strategy for clinicians is a challenge.This study retrospectively collected the medical information of patients with refractory advanced breast cancer who were treated with bevacizumab in our department to analyze the efficacy and safety of bevacizumab-containing as a new treatment method for refractory advanced breast cancer.Methods: Complete medical information of patients receiving bevacizumab treatment from November 2017 to November 2020 was collected, and their general medical history and disease characteristics were analyzed. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to failure (TTF), overall survival (OS), and safety were analyzed using SPSS 20.0 statistical software.Results: A total of 68 women with refractory advanced breast cancer receiving bevacizumab-containing therapy were collected. The last follow-up was performed on March 31, 2021. The ORR was 41.2% and the DCR was 88.2%. The median PFS, TTF, and OS were 6.0 months (95% CI, 3.4~8.6 months), 4.0 months (95% CI, 3.2~4.8 months), and 26.6 months (95% CI, 10.2~43.0 months), respectively. In 2 patients, the treatment was discontinued because of chemo-related adverse reactions. The main adverse events related to bevacizumab were hypertension (7.4%) and bleeding (two cases, 2.9%), both of which were grade 1. No specific adverse events causing the discontinuation of bevacizumab treatment were observed in the remaining patients.Conclusion: Among patients with refractory advanced breast cancer, bevacizumab-containing therapyis feasible and safe, and can be used as a new treatment strategy.However, who can benefit the most from bevacizumab-containing therapy requires further exploration.
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
